Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.

Preparation

The antibody was purified by affinity chromatography.

Concentration

0.5 mg/ml

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested
IHC-F - Reported in the literature, not verified in house

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is ≤0.25 ?g per million cells in 100 ?l volume. It is recommended that the reagent be titrated for optimal performance for each application.

Application Notes

The OKT3 monoclonal antibody reacts with an epitope on the epsilon-subunit within the human CD3 complex.

Clone OKT3 can block the binding of clones SK7 and UCHT1.⁴ The OKT3 antibody is able to induce T cell activation. Additional reported applications (for the relevant formats) include: immunohistochemical staining of acetone-fixed frozen sections and activation of T cells. The LEAF? purified antibody (Endotoxin <0.1 EU/?g, Azide-Free, 0.2 ?m filtered) is recommended for functional assays (Cat. No. 317304). For highly sensitive assays, we recommend Ultra-LEAF? purified antibody (Cat. No. 317326) with a lower endotoxin limit than standard LEAF? purified antibodies (Endotoxin <0.01 EU/?g).

Application References

(PubMed link indicates BioLegend citation)

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Li B, et al. 2005. Immunology 116:487.
5. Jeong HY, et al. 2008. J. Leuckocyte Biol. 83:755. PubMed
6. Alter G, et al. 2008. J. Virol. 82:9668. PubMed
7. Manevich-Mendelson E, et al. 2009. Blood 114:2344. PubMed
8. Pinto JP, et al. 2010. Immunology. 130:217. PubMed
9. Biggs MJ, et al. 2011. J. R. Soc. Interface. 8:1462. PubMed

Product Citations

1. Mousset CM, et al. 2018. Oncoimmunology. 7:e1488565. PubMed
2. Jeong H, et al. 2008. J Leukoc Biol. 83:755. PubMed
3. Biggs M, et al. 2011. J R Soc Interface. 1.348611111. PubMed
4. Mammadli M, et al. 2021. Clin Transl Med. 11:e625. PubMed
5. Blas-Rus N, et al. 2016. Nat Commun. 7: 11389. PubMed
6. Mehta N, et al. 2020. Sci Rep. 10:15171. PubMed
7. Alcántara‐Hernández M et al. 2017. Immunity. 47(6):1037-1050 . PubMed
8. Li G, et al. 2021. Oncoimmunology. 10:1983306. PubMed
9. Weinhage T, et al. 2020. J Immunol. 205:56. PubMed
10. Berkson JD, et al. 2020. Immunohorizons. 4:14. PubMed
11. Barzilai S, et al. 2017. Cell Rep. 18(3):685-699. PubMed
12. Bae EA, et al. 2018. Cancer Res. 78:5315. PubMed
13. Liang J, et al. 2017. Nat Commun. 8:15732. PubMed
14. Ghosh S, et al. 2020. Cell Reports. 30(10):3434-3447. PubMed
15. Willing A, et al. 2018. J Immunol. 200:974. PubMed
16. Bluhm J, et al. 2018. Mol Ther. 26:1906. PubMed
17. Yarzabek B et al. 2018. eLife. 7 pii: e34961. PubMed
18. Lang C, Wang J, and Chen L 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.09.030. PubMed
19. Fronik P, et al. 2021. J Med Chem. 64:12132. PubMed
20. Amiad-Pavlov D, et al. 2021. Sci Adv. 7: . PubMed
21. Nissim L et al. 2017. Cell. 171(5):1138-1150 . PubMed
22. García–Ortiz A, et al. 2017. PLoS Biol. 15:e2000653. PubMed
23. Kujawski M, et al. 2019. BMC Cancer. 1.404166667. PubMed
24. Willimsky G, et al. 2021. Elife. 10:. PubMed
25. Mann ER, et al. 2020. Sci Immunol. :5. PubMed
26. Nathan A, et al. 2021. Cell. 184(17):4401-4413.e10. PubMed
27. Kaufmann M, et al. 2021. Med. 2(3):296-312.e8. PubMed
28. Holbrook AK, et al. 2019. Physiol Rep. 7:e14234. PubMed
29. Winkler M, et al. 2017. PLoS One.. 10.1371/journal.pone.0182427. PubMed
30. Dilchert J, et al. 2022. Antibodies (Basel). 11:. PubMed
31. Alcántara-Hernández M, et al. 2021. Nat Protoc. 16:4855. PubMed
32. Xiong Y, et al. 2019. J Immunol. 203:3023. PubMed
33. Kessel C, et al. 2017. Arthritis Rheumatol. 69:1480. PubMed
34. Fu Z, et al. 2021. Acta Pharm Sin B. 11:3925. PubMed
35. Wilson AS, et al. 2022. Nat Commun. 13:528. PubMed
36. Jilg N, et al. 2020. J Infect Dis. 222:1837. PubMed
37. Hu X, et al. 2021. British Journal of Pharmacology. 178(6):1445-1458. PubMed
38. Bertino P, et al. 2019. Oncoimmunology. 8:1601482. PubMed
39. Li L, et al. 2020. J Transl Med. 18:363. PubMed
40. Broos K, et al. 2019. Cancers (Basel). 11. PubMed
41. Zhao R, et al. 2018. Oncoimmunology. 8:e1509173. PubMed
42. Li H, et al. 2020. Front Immunol. 11:1777. PubMed
43. Hsu CY, et al. 2020. Frontiers in Immunology. 11:574839. PubMed
44. Walk J, et al. 2020. Front Immunol. 2.405555556. PubMed
45. Johnston HE, et al. 2018. Mol Cell Proteomics. 1.247222222. PubMed
46. Thomi R, et al. 2017. Br J Dermatol.. 10.1111/bjd.15458. PubMed
47. Kim G, et al. 2021. J Infect Dis. 224:1861. PubMed
48. Herati RS, et al. 2021. Cell Reports Medicine. 2(5):100262. PubMed
49. Mayer KE, et al. 2019. Theranostics. 4.548611111. PubMed
50. Tripathi T, et al. 2019. Immunohorizons. 0.201388889. PubMed
51. Alter G, et al. 2008. J Virol. 82:9668. PubMed
52. Gurusamy M, et al. 2021. Nat Commun. 12:6798. PubMed
53. Zu?iga J, et al. 2020. Int J Infect Dis. 94:4. PubMed
54. Wang Q, et al. 2020. J Immunother Cancer. 8:. PubMed
55. Glud EN, et al. 2022. Br J Cancer. Online ahead of print. PubMed
56. Pinto J, et al. 2010. Immunology. 130:217. PubMed
57. Auladell M, et al. 2019. Clin Transl Immunology. 8:e01090. PubMed
58. Seo N, et al. 2018. Nat Commun. 9:435. PubMed
59. Qiu H, et al. 2017. Exp Cell Res.. 10.1016/j.yexcr.2017.08.036. PubMed
60. Jin Y, et al. 2017. Int Immunopharmacol. . 10.1016/j.intimp.2017.10.009. PubMed
61. Schoknecht T, et al. 2017. J Leukoc Biol. 101:589. PubMed
62. Escudero–Pérez B, et al. 2019. JCI Insight. 4:e126070. PubMed
63. Guo J, et al. 2022. J Immunother Cancer. 10:. PubMed
64. Wiedeman AE, et al. 2020. J Clin Invest. 130:480. PubMed
65. Rivera-Cruz CM, et al. 2022. Cytotherapy. Online ahead of print. PubMed
66. Park S, et al. 2020. Biosens Bioelectron. 112389:165. PubMed
67. Henrick BM, et al. 2021. Cell. . PubMed
68. Zavidij O, et al. 2020. Nat Cancer. 0.384027778. PubMed
69. Manevich-Mendelson E, et al. 2009. Blood. 114:2344. PubMed
70. Caielli S, et al. 2019. Nat Med. 25:75. PubMed
71. Ardain A, et al. 2019. Nature. 570:528. PubMed
72. Horn LA, et al. 2017. Oncotarget. 8:57964. PubMed
73. Singh AK, et al. 2017. Front Immunol. 0.513888889. PubMed
74. Lee YS, et al. 2021. J Immunother Cancer. 9:. PubMed
75. Bacot SM, et al. 2020. Int J Mol Sci. 21:. PubMed
76. Hirama T, et al. 2021. JCI Insight. 6:. PubMed
77. Levin SD, et al. 2020. Front Immunol. 10:3086. PubMed
78. Pawlak EN, et al. 2018. Retrovirology. 15:6. PubMed
79. Meng Q, et al. 2018. Sci Rep. 8:17079. PubMed
80. Boutboul D, et al. 2018. J Clin Invest. 128:3071. PubMed
81. Chevalier MF, et al. 2017. J Clin Invest. 127:2916. PubMed
82. Carriche GM, et al. 2021. J Allergy Clin Immunol. 147:335. PubMed
83. Pan Y, et al. 2021. Br J Pharmacol. 178:4907. PubMed
84. Benabdallah B, et al. 2019. Front Immunol. 10:2580. PubMed
85. Sneddon S, et al. 2020. Oncoimmunology. 9:1684713. PubMed
86. Moosmann C, et al. 2022. STAR Protoc. 3:101031. PubMed
87. Cassioli C, et al. 2021. Front Cell Dev Biol. 9:673446. PubMed
88. Müller TR, et al. 2021. Cell Rep Med. 2:100374. PubMed
89. Crome SQ, et al. 2017. Nat Med. 1.213888889. PubMed
90. Hashimoto M, et al. 2017. Int J Inflam. 2017:1324735. PubMed
91. Siegers GM, et al. 2020. Front Immunol. 1.352083333. PubMed
92. Garcia de Moura R, et al. 2021. Front Immunol. 12:632667. PubMed
93. Naranbhai V, et al. 2022. Cell. . PubMed
94. Yang J, et al. 2020. Nat Commun. 11:4402. PubMed
95. Chevrier S, et al. 2021. Cell Reports Medicine. 2(1):100166. PubMed
96. Srivastava S, et al. 2020. Cancer Cell. 39(2):193-208.e10. PubMed
97. He Y, et al. 2021. eLife. 10:00. PubMed
98. Yin Y, et al. 2017. J Allergy Clin Immunol. 139:1701. PubMed
99. Malenica I, et al. 2021. Nat Commun. 12:5209. PubMed
100. Liu Z, et al. 2017. Oncotarget. 8:53518. PubMed
101. Terzuoli E, et al. 2019. Cancers (Basel). 1.821527778. PubMed
102. Akhand SS, et al. 2020. Cancer Immunol Res. 8:1542. PubMed
103. Welch JL, et al. 2020. FEBS Lett. 594:695. PubMed
104. Leylek R, et al. 2020. Cell Rep. 32:108180. PubMed
105. Dutertre CA, et al. 2020. Immunity. 51(3):573-589.e8.. PubMed
106. Chiou SH, et al. 2021. Immunity. 54:586. PubMed
107. Shalata W, et al. 2021. Cancers (Basel). 13: . PubMed

RRID

AB_571926 (BioLegend Cat. No. 317301) AB_571927 (BioLegend Cat. No. 317302)